Combined metformin and progestin in endometrial cancer with Jennifer Chae-Kim

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Jennifer Chae-Kim. Dr. Chae-Kim is the author of Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis, which is the Lead Article of IJGC’s December 2021 issue. Dr. Chae-Kim is in her last year of OB/GYN residency at BSW-Temple, and will be pursuing her interests in fertility preservation and fellowship training in REI at the NIH next year. https://ijgc.bmj.com/content/early/2021/11/15/ijgc-2021-002699 Jennifer Chae-Kim (@chae_md) Highlights 1) Endometrial cancer and atypical endometrial hyperplasia are being diagnosed more frequently in reproductive-aged women, who may desire fertility-sparing therapy. 2) Women who received progestin and metformin therapy were found to have lower disease relapse rates than those who received progestin alone. 3) Combined therapy was not associated with significantly different rates of disease remission, pregnancy, live birth.

4) Further research is needed to determine the parameters of clinical application of metformin to progestin therapy.